U.S. Pay-To-Delay Suit Against Ranbaxy, Pfizer Rejected
This article was originally published in PharmAsia News
Executive Summary
A U.S. judge threw out a suit filed against Ranbaxy Laboratories and Pfizer alleging they colluded to delay the market introduction of a generic of the top-selling Lipitor (atorvastatin) for high cholesterol.